Dichloroacetate - Saol therapeutics
Alternative Names: Dichloroacetate sodium; SIL-1009; SL-1009; Sodium Dichloroacetate- DCALatest Information Update: 10 Dec 2024
Price :
$50 *
At a glance
- Originator Saol Therapeutics
- Developer Food and Drug Administration; National Institute of Child Health and Human Development; Saol Therapeutics; University of Florida
- Class Acetates; Antineoplastics; Neuroprotectants; Nootropics; Small molecules
- Mechanism of Action Pyruvate dehydrogenase complex stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Metabolic disorders
Most Recent Events
- 10 Dec 2024 Dichloroacetate - Saol therapeutics receives Rare Pediatric Disease designation by US FDA for Metabolic disorders in USA
- 04 Dec 2024 Phase-III clinical trials in Metabolic disorders (In infants, In children, In adolescents) (PO)
- 04 Dec 2024 Preregistration for Metabolic disorders (In adolescents, In children, In infants) in USA (PO)